JP2018525447A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525447A5
JP2018525447A5 JP2018530646A JP2018530646A JP2018525447A5 JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5 JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5
Authority
JP
Japan
Prior art keywords
compound
halogenated
optionally
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018530646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049271 external-priority patent/WO2017035529A1/en
Publication of JP2018525447A publication Critical patent/JP2018525447A/ja
Publication of JP2018525447A5 publication Critical patent/JP2018525447A5/ja
Pending legal-status Critical Current

Links

JP2018530646A 2015-08-27 2016-08-29 App選択的bace阻害のための組成物およびそのための使用 Pending JP2018525447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210945P 2015-08-27 2015-08-27
US62/210,945 2015-08-27
PCT/US2016/049271 WO2017035529A1 (en) 2015-08-27 2016-08-29 Compositions for app-selective bace inhibition and uses therfor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020152650A Division JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Publications (2)

Publication Number Publication Date
JP2018525447A JP2018525447A (ja) 2018-09-06
JP2018525447A5 true JP2018525447A5 (enExample) 2019-08-29

Family

ID=58101012

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530646A Pending JP2018525447A (ja) 2015-08-27 2016-08-29 App選択的bace阻害のための組成物およびそのための使用
JP2020152650A Pending JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020152650A Pending JP2021001188A (ja) 2015-08-27 2020-09-11 App選択的bace阻害のための組成物およびそのための使用

Country Status (8)

Country Link
US (1) US11142505B2 (enExample)
EP (1) EP3341362B1 (enExample)
JP (2) JP2018525447A (enExample)
KR (1) KR20180090778A (enExample)
CN (1) CN108349905A (enExample)
AU (1) AU2016311502B2 (enExample)
CA (2) CA3096896A1 (enExample)
WO (1) WO2017035529A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899938C (en) * 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
KR20180090778A (ko) * 2015-08-27 2018-08-13 난트뉴로, 엘엘씨 App-선택적 bace 억제를 위한 조성물 및 그의 용도
US20210101879A1 (en) * 2018-03-01 2021-04-08 The Regents Of The University Of California AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992013069A1 (en) 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
DK0620849T3 (da) 1992-01-07 2003-10-20 Elan Pharm Inc Transgene dyremodeller for Alzheimer's sygdom
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
WO1995011968A1 (en) 1993-10-27 1995-05-04 Athena Neurosciences, Inc. Transgenic animals harboring app allele having swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
NZ510708A (en) 1998-09-24 2003-12-19 Upjohn Co Alzheimer's disease and Asp1 and Asp2 cleaving APP site (beta secretase)
ATE444962T1 (de) * 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
JP2009500329A (ja) * 2005-06-30 2009-01-08 ワイス アミノ−5−(6員)ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用
AU2006294620A1 (en) * 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
JP2009520027A (ja) 2005-12-19 2009-05-21 ワイス 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
US9980769B2 (en) 2014-04-08 2018-05-29 Ethicon Llc Methods and devices for controlling motorized surgical devices
KR20180090778A (ko) 2015-08-27 2018-08-13 난트뉴로, 엘엘씨 App-선택적 bace 억제를 위한 조성물 및 그의 용도
US20200165225A1 (en) 2017-06-28 2020-05-28 Nantbio, Inc. Bace1 inhibitors for treatment of alzheimer's disease
US20210101879A1 (en) 2018-03-01 2021-04-08 The Regents Of The University Of California AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE

Similar Documents

Publication Publication Date Title
de Boer et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study
JP2016040288A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2015511638A5 (enExample)
JP2013513613A5 (enExample)
JP2018518537A5 (enExample)
JP2013501731A5 (enExample)
JP2006501240A5 (enExample)
JP2009533356A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2008534453A5 (enExample)
JP2016503797A5 (enExample)
JP2018525447A5 (enExample)
JP2015535247A5 (enExample)
JP2009511568A5 (enExample)
JP2010532383A5 (enExample)
JP2019516739A5 (enExample)
JP2019520344A5 (enExample)
RU2008139195A (ru) Замещенные арилсульфанамиды как противовирусные средства
RU2019111421A (ru) Способы лечения острого повреждения почек
JP2016537338A5 (enExample)
CN105228622A (zh) 用于治疗多发性硬化的PPARγ激动剂
JP2020500868A5 (enExample)
JP2016537432A5 (enExample)
JP2019531286A5 (enExample)